Actuate Therapeutics, Inc. Common stock (ACTU) is a publicly traded Healthcare sector company. As of May 21, 2026, ACTU trades at $2.51 with a market cap of $58.14M and a P/E ratio of -2.36. ACTU moved +3.33% today. Year to date, ACTU is -60.41%; over the trailing twelve months it is -76.32%. Its 52-week range spans $1.58 to $11.99. Analyst consensus is buy with an average price target of $13.50. Rallies surfaces ACTU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Actuate Therapeutics Targets $200M+ Pediatric Voucher with Oral Elraglusib and RAS Trials: Actuate Therapeutics reported complete responses in pediatric Ewing sarcoma and neuroblastoma, qualifying elraglusib for Rare Pediatric Disease Designation and a potential Priority Review Voucher worth $150–200M upon FDA approval. The company’s oral elraglusib shows ~51% bioavailability and it’s launching RAS inhibitor combination trials in H2 2026.
| Metric | Value |
|---|---|
| Price | $2.51 |
| Market Cap | $58.14M |
| P/E Ratio | -2.36 |
| EPS | $-1.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.99 |
| 52-Week Low | $1.58 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-22.23M |
| Gross Margin | 0.00% |
2 analysts cover ACTU: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.50.